Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial-Reference-Cited by-同舟云学术

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial

Published:2021-06-21 Issue:9 Volume:23 Page:1518-1524
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Bhatt Ankeet S.¹,Vaduganathan Muthiah¹,Claggett Brian L.¹,Liu Jiankang¹,Packer Milton²,Desai Akshay S.¹,Lefkowitz Martin P.³,Rouleau Jean L.⁴,Shi Victor C.³,Zile Michael R.⁵,Swedberg Karl⁶,Vardeny Orly⁷,McMurray John J.V.⁸,Solomon Scott D.¹

Affiliation:

1. Division of Cardiology Brigham and Women's Hospital Boston MA USA

2. Baylor Heart and Vascular Institute, Baylor University Medical Center Dallas TX USA

3. Novartis Pharmaceuticals Corporation East Hanover NJ USA

4. Montreal Heart Institute, Université de Montréal Montréal QC Canada

5. Medical University of South Carolina, Charleston and Ralph H. Johnston Veterans Administration Medical Center Charleston SC USA

6. Department of Molecular and Clinical Medicine University of Gothenburg Gothenburg Sweden

7. Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, and University of Minnesota Minneapolis MN USA

8. British Heart Foundation Cardiovascular Research Centre, University of Glasgow Glasgow UK

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2259

Reference16 articles.

1. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

2. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

3. Medical Therapy for Heart Failure With Reduced Ejection Fraction

4. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

5. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM‐HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor with Angiotensin‐Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure);Vardeny O;Circ Heart Fail,2018

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decrypting the role of angiogenesis, inflammation, and oxidative stress in pathogenesis of congestive heart failure: Nanotechnology as a boon for the management of congestive heart failure;Targeting Angiogenesis, Inflammation, and Oxidative Stress in Chronic Diseases;2024

2. Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure;American Journal of Cardiovascular Drugs;2023-08-24

3. Management of Worsening Heart Failure With Reduced Ejection Fraction;Journal of the American College of Cardiology;2023-08

4. Management of Heart Failure With Reduced Ejection Fraction;Current Problems in Cardiology;2023-05

5. Sacubitril/Valsartan in Heart Failure Hospitalization: Two Pills a Day to Keep Hospitalizations Away?;Cureus;2023-04-09